A randomized study shows that the mpMRI-first approach reduced the time to treatment by 45 days (53 vs. 98 days). No harm to non-MIBC patients. A game-changer for staging? #Oncology @oncoalert.bsky.social
ascopubs.org/doi/10.1200/JC…
A randomized study shows that the mpMRI-first approach reduced the time to treatment by 45 days (53 vs. 98 days). No harm to non-MIBC patients. A game-changer for staging? #Oncology @oncoalert.bsky.social
ascopubs.org/doi/10.1200/JC…
www.europeanurology.com/article/S030...
www.europeanurology.com/article/S030...
@nikhilmayor.bsky.social gives an update on the #IP7PACIFIC trial with >1,000 patients recruited so far #EAU25 🇪🇸
@nikhilmayor.bsky.social gives an update on the #IP7PACIFIC trial with >1,000 patients recruited so far #EAU25 🇪🇸
@cancerresearchuk.org #ClinicalResearchMeeting
#SPACE_Study
@ndsurgicalsci.bsky.social
@oxfordcancer.bsky.social
@cancerresearchuk.org #ClinicalResearchMeeting
#SPACE_Study
@ndsurgicalsci.bsky.social
@oxfordcancer.bsky.social
@oncoalert.bsky.social @apccc.bsky.social
@oncbrothers.bsky.social @jama.com
@oncoalert.bsky.social @apccc.bsky.social
@oncbrothers.bsky.social @jama.com
@yukselurun.bsky.social
oncodaily.com/science/yuks...
#AnkaraUniversity #BRCA #Cancer #FightAgainstCancer #Lenvatinib #mCRPC #mpMRI #OncoDaily #Oncology #Pembrolizumab #ProstateCancer #UrothelialCarcinoma
@yukselurun.bsky.social
oncodaily.com/science/yuks...
#AnkaraUniversity #BRCA #Cancer #FightAgainstCancer #Lenvatinib #mCRPC #mpMRI #OncoDaily #Oncology #Pembrolizumab #ProstateCancer #UrothelialCarcinoma
@yukselurun.bsky.social
oncodaily.com/science/225249
#BladderCancer #BreastCancer #Cancer #Cytokines #Medicine #Epidemiology #ESMO #GlobalConsortium #Oncology #GBMGrowth #Health #TransurethralResection #MagneticResonanceImaging #MedOnc #mpMRI #OncoDaily
A new study shows multiparametric MRI (mpMRI) can reliably detect clinically significant prostate cancer and exclude it in patients with non-suspicious MRI findings, even with highly elevated PSA.
A new study shows multiparametric MRI (mpMRI) can reliably detect clinically significant prostate cancer and exclude it in patients with non-suspicious MRI findings, even with highly elevated PSA.
by Bryan RT, Liu W (...) James ND et 24 al. in J Clin Oncol #MedSky
📖 read the article: https://doi.org/10.1200/JCO.23.02398
by Bryan RT, Liu W (...) James ND et 24 al. in J Clin Oncol #MedSky
📖 read the article: https://doi.org/10.1200/JCO.23.02398
This will be the first trial to provide definitive evidence comparing bpMRI vs mpMRI, alongside fusion vs cognitive biopsy
>1200 patients recruited across the UK - watch this space
This will be the first trial to provide definitive evidence comparing bpMRI vs mpMRI, alongside fusion vs cognitive biopsy
>1200 patients recruited across the UK - watch this space
ja.ma/4m9lkAk
www.ajronline.org/doi/10.2214/...
www.ajronline.org/doi/10.2214/...
PSA/bpMRI SOC ->
makes PSA/bpMRI population screening feasible
Except: PSMA PET to eventually replace bpMRI upfront:
- diagnose + stage in 1 scan
- less reader variation
- reserve MRI for anatomical detail/focal therapy planning.
Meanwhile, learn to read MRI!
mripro.io
PSA/bpMRI SOC ->
makes PSA/bpMRI population screening feasible
Except: PSMA PET to eventually replace bpMRI upfront:
- diagnose + stage in 1 scan
- less reader variation
- reserve MRI for anatomical detail/focal therapy planning.
Meanwhile, learn to read MRI!
mripro.io
#EuropeanRadiologyExperimental
buff.ly/6IeQEiA 2/2
#EuropeanRadiologyExperimental
buff.ly/6IeQEiA 2/2
buff.ly/6IeQEiA
buff.ly/6IeQEiA